Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Latest Information Update: 15 Jan 2024
At a glance
- Drugs Ibrutinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors US Oncology Research
- 11 Jan 2024 Planned End Date changed from 31 Dec 2023 to 1 Jun 2024.
- 11 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 1 Jun 2024.
- 09 Dec 2023 Results assessing safety and efficacy of ibrutinib in combination with trastuzumab in patients (pts) with HER2-positive metastatic breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium